Myocardial Ischemia and Infarction

Journal of the American College of Cardiology

Volumn 47, Issue 11 SUPPL., 2006, Pages

  Ambrose, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; TRANDOLAPRIL;

ACUTE CORONARY SYNDROME; ADIPOSE TISSUE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; GENOMICS; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MORTALITY; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; STENT; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; CORONARY ARTERIOSCLEROSIS; FIBRINOLYTIC AGENTS; GENOMICS; HUMANS; KIDNEY; LIPIDS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; STEM CELL TRANSPLANTATION; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 33646925388     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.04.013     Document Type: Review

References (16)

1. Steg P.G., Bhatt D.L., Wilson P.W.F., et al., REACH Registry Investigators. Reduction of atherothrombosis for continued health (REACH) registry results. 1-year cardiovascular event rates in a global contemporary registry of over 68,000 outpatients with atherothrombosis. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 168A
2. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) Mar 21 [epub ahead of print].
3. Stone G.W., and ACUITY Investigators. Prospective, randomized comparison of routine upfront initiation versus selective use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes. the ACUITY Timing Trial (2006) Presented at: ACC 55th Annual Scientific Session; Atlanta, GA: March 11-14
4. Kastrati A., and ISAR-REACT 2 Investigators. Prospective, randomized, double blind, placebo controlled trial of glycoprotein IIb/IIIa inhibition with abciximab in patients with acute coronary syndromes undergoing stenting after pretreatment with a high loading dose of clopidogrel (2006) Presented at: ACC 55th Annual Scientific Session; Atlanta, GA: March 11-14
5. Yusuf S., Mehta S.R., Chrolavicius S., et al., OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
6. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
7. Solomon S.D., Rice M.M., Jablonski K., et al. Reduced renal function is associated with increased effectiveness of ACE inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 162A
8. Ahmed S., Cannon C.P., Giugliano R.P., et al. The independent and combined risks of diabetes and non-endstage renal impairment in non ST-segment elevation acute coronary syndromes. (abstr). J Am Coll Cardiol 47 SupplA (2006) 207A
9. Fox K.A.A., Bassand J.P., Wallentin L., et al. The efficacy and safety of fondaparinux vs. enoxaparin in non-ST elevation ACS. impact of renal dysfunction (OASIS 5). (abstr). J Am Coll Cardiol 47 Suppl A (2006) 195A
10. Cullen M.W., Gangnon R.E., McBride P.E., Stein J.H., and Keevil J.G. National improvements in the recognition and treatment of patients at increased coronary risk. the National Health and Nutrition Examination Survey, 1999-2002. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 169A
11. Steinberg B.A., O'Hagen P., Chadwell P., Turner G., and Cannon C.P. Statin use and low-density cholesterol goals in 2004. how are we doing applying National Cholesterol Education Program III guidelines. (abstr)?. J Am Coll Cardiol 47 Suppl A (2006) 209A
12. Chen M.S., Jia G., Luke M.M., et al. Genomic association of graft failure of the left internal thoracic artery for myocardial revascularization. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 165A
13. Björkland E., Stenestrand U., Lindbäck J., et al. A prehospital diagnostic strategy reduces time to treatment and mortality in real life patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. (abstr). J Am Coll Cardiol 74 Suppl A (2006) 192A
14. Morice M.-C., Spaulding C., Lancelin B., et al. Does hospital PTCA volume influence mortality and complication rates in the era of PTCA with systematic stenting? Results of the Greater Paris PTCA registry. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 192A
15. Spertus J.A., Kettelkamp R., Vance C., et al. Incidence of, predictors of, and outcomes related to discontinuation of thienopyridine therapy at 1-month after coronary stenting in AMI. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 236A
16. Matthias N., Schwarzer M., Pinkernell K., Fotuhi P., and Alt E. Effect of stem cells on left ventricle wall thickness and capillary density in pigs following myocardial infarction. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 206A